Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether policies to improve patient access to combination therapies will be considered by his Department in upcoming negotiations for the 2024 Voluntary Scheme for Branded Medicines Pricing and Access.

The Department is considering how a successor to the voluntary scheme for branded medicines pricing and access should operate from 2024 onwards and will work with industry to agree a mutually beneficial successor that that supports better patient outcomes, ensuring the sustainability of National Health Service spend on branded medicines and enables a strong United Kingdom life sciences industry.